FY2024 Earnings Forecast for VYGR Issued By HC Wainwright

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – HC Wainwright lifted their FY2024 earnings estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.82) per share for the year, up from their previous forecast of ($0.97). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($1.69) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the business posted ($0.59) EPS.

Several other equities research analysts have also commented on VYGR. Leerink Partners began coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Wedbush reduced their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday. Finally, StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, November 10th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $5.64 on Monday. The firm has a market capitalization of $308.11 million, a PE ratio of 7.94 and a beta of 0.89. Voyager Therapeutics has a 1-year low of $5.59 and a 1-year high of $11.72. The business’s fifty day moving average price is $6.62 and its two-hundred day moving average price is $7.49.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. grew its holdings in shares of Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in Voyager Therapeutics during the 1st quarter worth about $38,000. China Universal Asset Management Co. Ltd. lifted its stake in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Voyager Therapeutics during the third quarter valued at about $74,000. Finally, SG Americas Securities LLC acquired a new position in shares of Voyager Therapeutics in the second quarter worth about $85,000. Institutional investors own 48.03% of the company’s stock.

Insider Buying and Selling

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.53% of the stock is owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.